Efficacy of combination antiplatelet therapy and nicardipine for chronic cerebral infarction.

Abstract

To prevent recurrence of cerebral infarction (CI), the efficacy of antiplatelet therapy, when used in combination with a calcium antagonist, was examined. The study subjects were 57 chronic CI patients (40 men, 17 women; mean age, 68.5 years) who experienced either CI or its recurrence more than 3 months before the start of the study. They were randomly allocated into one of the following four groups for the 8-week study; group A--ticlopidine hydrochloride 200 mg once daily and nicardipine hydrochloride 20 mg three times daily (TID); group B--ticlopidine hydrochloride 200 mg once daily; group C--aspirin 81 mg once daily and nicardipine hydrochloride 20 mg TID; or group D--aspirin 81 mg once daily. Platelet aggregation was measured before treatment and 4 and 8 weeks after the initiation of each therapy by using adenosine diphosphate (ADP) (2 microM and 0.5 microM) and collagen (2 micrograms/mL), and evaluated in terms of percent maximum platelet aggregation. Results showed significant suppression of 2.0 microM ADP platelet aggregation in groups A, B, and C. At 0.5-microM ADP, only groups A and B showed significant platelet aggregation suppression. All groups showed significant suppression of collagen platelet aggregation. In comparing single therapy with combination therapy, groups A and B were not significantly different from one another after 4 or 8 weeks in 2-microM ADP or collagen platelet aggregation suppression. In contrast, group C had significantly greater suppression of both 2-microM ADP and collagen aggregations compared with group D. In conclusion, nicardipine hydrochloride administration with aspirin may be a useful alternative therapy for the prevention of CI recurrence.

• Authors: H Nomura, C Morita, S Kuwano, H Eto, H Goto, H Kuwahara
• Journal: Clinical therapeutics (Clin Ther) 1996 May-Jun Vol. 18 Issue 3 Pg. 483-90 ISSN: 0149-2918 [Print] United States
• PMID: 8829024 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Calcium Channel Blockers
• Platelet Aggregation Inhibitors
• Adenosine Diphosphate
• Collagen
• Nicardipine
• Ticlopidine
• Aspirin

Topics

• Adenosine Diphosphate (antagonists & inhibitors, pharmacology)
• Aged
• Aspirin (therapeutic use)
• Calcium Channel Blockers (therapeutic use)
• Cerebral Infarction (blood, drug therapy)
• Chronic Disease
• Collagen (antagonists & inhibitors, pharmacology)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Nicardipine (therapeutic use)
• Platelet Aggregation (drug effects)
• Platelet Aggregation Inhibitors (therapeutic use)
• Ticlopidine (therapeutic use)